-
Visen Pharmaceuticals’ TransCon hGH Accepted for Review by China’s NMPA
•
Visen Pharmaceuticals, a joint venture between Denmark-based Ascendis Pharma and Chinese healthcare-focused investment firm Vivo Capital, has announced that the National Medical Products Administration (NMPA) has accepted for review a marketing approval filing for its lonapegsomatropin, TransCon hGH, a once-weekly long-acting growth hormone. This drug, which is the first long-acting…
-
Shandong Luoxin Pharmaceutical Partners with Xbiome to Access Microbiome Transplantation Technology
•
Shandong Luoxin Pharmaceutical Group Stock Co., Ltd (SHE: 002793), a pharmaceutical company based in China, has entered into a strategic partnership with Xbiome, a compatriot firm specializing in AI-based microbiome drug development. This collaboration grants Luoxin access to Xbiome’s advanced intestinal microbiota transplantation medical technology, marking a significant step in…
-
Shanghai Fosun Pharma Gets NMPA Green Light for Universal NK Cell Therapy GCK-01 Clinical Study
•
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196), a leading pharmaceutical company based in China, has announced that it has received approval from the National Medical Products Administration (NMPA) to conduct a Phase I clinical study for its universal NK cell therapy, GCK-01. This Category 1 innovative therapeutic…
-
Novo Nordisk’s Anti-Obesity Drug Wegovy Eyed for China Launch in 2024
•
Novo Nordisk (NYSE: NVO), a leading diabetes company based in Denmark, has reportedly informed investors that its anti-obesity drug Wegovy (semaglutide) is anticipated to receive approval and launch in China by the end of this year. Christine Zhou Xiaping, the head of Novo Nordisk’s China business, shared this update during…
-
China Grand Pharmaceutical Receives FDA Approval for Post-Surgical Ophthalmic Drug GPN00833
•
China Grand Pharmaceutical and Healthcare Holdings Ltd (HKG: 0512; CGP) has announced that it has received marketing approval from the US Food and Drug Administration (FDA) for its hormone nanosuspension eye drops GPN00833 (APP13007), designed for anti-inflammatory and analgesic effects following ophthalmic surgery. Additionally, the company has gained clinical trial…
-
Shanghai Fosun Pharma Gets NMPA Green Light for XS-02 Solid Tumor Clinical Study
•
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196), a leading pharmaceutical company based in China, has announced that it has received approval from the National Medical Products Administration (NMPA) to conduct a clinical study for its drug candidate XS-02 in patients with advanced solid tumors. XS-02 is a…
-
Everest Medicines to Establish Integrated Kidney Disease Diagnosis and Treatment Ecosystem
•
Everest Medicines (HKG: 1952), a Chinese pharmaceutical company, is set to collaborate with partners to create an innovative and integrated ecosystem focused on the diagnosis and treatment of kidney diseases. The company anticipates the imminent launch of a commercially valuable IgA kidney disease detection reagent, offering nephrologists and patients effective…
-
Boehringer Ingelheim’s Spevigo Receives NMPA Approval for GPP Treatment in China
•
German pharmaceutical giant Boehringer Ingelheim (BI) has announced that it has received marketing approval from China’s National Medical Products Administration (NMPA) for its biologic drug Spevigo (spesolimab) subcutaneous injection. The drug is indicated for reducing the incidence of generalized pustular psoriasis (GPP) in adolescents aged 12 and above weighing at…
